Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][8]. Core Insights - The company reported a revenue of 454.6 billion yuan for 2025, representing a year-on-year growth of 15.8%, and a net profit attributable to shareholders of 191.5 billion yuan, which is a significant increase of 102.6% [4][8]. - The Chemistry business showed stable growth with a revenue of 364.7 billion yuan in 2025, up 25.5%, while the TIDES business experienced remarkable growth, generating 113.7 billion yuan, a 96.0% increase [5][8]. - The company has a strong order backlog of 580 billion yuan, reflecting a year-on-year increase of 28.8% as of the end of 2025, with guidance for 2026 indicating an expected revenue of 513-530 billion yuan, representing a growth of 18-22% [7][8]. Summary by Relevant Sections Financial Performance - For Q4 2025, the company achieved a revenue of 126.0 billion yuan, up 9.2%, and a net profit of 70.8 billion yuan, which is a 142.5% increase [4]. - The overall gross margin for 2025 was 48.2%, an increase of 6.6 percentage points, while the Non-IFRS net profit margin was 32.9%, up 5.9 percentage points [7]. Business Segments - The Testing business generated 40.4 billion yuan in revenue for 2025, a growth of 4.7%, but faced margin pressure with a gross margin of 30.5%, down 5.7 percentage points [6]. - The Biology business reported a revenue of 26.8 billion yuan, up 5.5%, with a gross margin of 37.0%, down 1.9 percentage points [6]. Future Projections - Revenue projections for 2026, 2027, and 2028 are estimated at 521.6 billion yuan, 605.9 billion yuan, and 694.5 billion yuan, respectively, with year-on-year growth rates of 14.7%, 16.2%, and 14.6% [8][11]. - The forecasted net profit for 2026 is 163.9 billion yuan, reflecting a decrease of 14.4% year-on-year, followed by increases of 17.7% and 16.1% in the subsequent years [8][11].

Investment Rating - The report maintains a "BUY" rating for WuXi AppTec, with a target price raised to RMB133.00, indicating a potential upside of 42.0% from the current price of RMB93.68 [3][18]. Core Insights - WuXi AppTec reported a revenue growth of 15.8% YoY for 2025, with adjusted non-IFRS net profit increasing by 41.3% YoY, both figures surpassing estimates [1][2]. - Management projects 2026 revenue to reach RMB51.3-53.0 billion, with continuing operations expected to grow by 18-22% YoY [1]. - The backlog for continuing operations grew by 28.8% YoY to RMB58.0 billion, indicating strong demand for CDMO services [9]. - The company plans to increase capital expenditure to RMB6.5-7.5 billion in 2026, reflecting a commitment to global capacity expansion [9]. Financial Performance - Revenue projections for FY26E are RMB51,695 million, with a YoY growth of 13.7% [2]. - Adjusted net profit for FY26E is expected to be RMB17,930 million, reflecting a 19.9% YoY increase [2]. - The adjusted net profit margin is anticipated to remain stable, contributing to a robust financial outlook [1][9]. Valuation Metrics - The P/E ratio is projected to decrease from 17.9 in FY25A to 15.6 in FY26E, indicating improved valuation attractiveness [2][15]. - The gross profit margin is expected to improve to 48.5% in FY26E, up from 47.6% in FY25A [16]. Market Position - WuXi AppTec's market capitalization stands at RMB279,518.4 million, with a significant shareholding structure that includes 23.7% held by HK investors and 16.4% by Ge Li and concerted parties [4][5]. - The company has shown resilience in early-stage business recovery, with revenue growth in the Testing and Biology segments [9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][8]. Core Insights - The company reported a revenue of 45.46 billion yuan for 2025, representing a year-on-year growth of 15.8%, and a net profit attributable to shareholders of 19.15 billion yuan, which is a significant increase of 102.6% [4][8]. - The Chemistry business showed stable growth with a revenue of 36.47 billion yuan, up 25.5%, while the TIDES business experienced remarkable growth, with revenue reaching 11.37 billion yuan, up 96.0% [5][8]. - The company has a strong order backlog of 58 billion yuan, reflecting a year-on-year increase of 28.8% [7]. Financial Performance Summary - The company’s gross margin for 2025 was 48.2%, an increase of 6.6 percentage points, and the Non-IFRS net profit margin was 32.9%, up 5.9 percentage points [7]. - For Q4 2025, the revenue was 12.6 billion yuan, with a net profit of 7.08 billion yuan, marking a year-on-year increase of 142.5% [4][6]. - The projected revenues for 2026, 2027, and 2028 are 52.16 billion yuan, 60.59 billion yuan, and 69.45 billion yuan, respectively, with expected growth rates of 14.7%, 16.2%, and 14.6% [8][11]. Business Segment Performance - The Testing business generated a revenue of 4.04 billion yuan in 2025, growing by 4.7%, but faced margin pressure with a gross margin of 30.5%, down 5.7 percentage points [6]. - The Biology business reported a revenue of 2.68 billion yuan, up 5.5%, with a gross margin of 37.0%, down 1.9 percentage points [6]. Valuation Metrics - The company’s projected P/E ratios for 2026, 2027, and 2028 are 17, 15, and 12, respectively, indicating a favorable valuation outlook [8][11]. - The projected EPS for the same years is 5.49 yuan, 6.46 yuan, and 7.50 yuan [11]. Conclusion - The report highlights the company's strong market position as a leading integrated drug development service platform, with expectations for continued growth in its core Chemistry business and stable profitability [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年3月24日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 2025 年年度股东会、2026 年第一次 A 股类别股东会及 2026 年第一次 H 股类 别股东会 会议材料 二〇二六年四月 1 无锡药明康德新药开发股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年3月24日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2026-015 无锡药明康德新药开发股份有限公司 关于召开2025年年度股东会、2026 年第一次 A 股类别股东 会及 2026 ...

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec exceeded its annual guidance, achieving record high performance in 2025 with a revenue of 45.456 billion yuan, a year-on-year increase of 15.8%. The adjusted net profit attributable to shareholders reached 14.96 billion yuan, up 41.3% year-on-year [4][5]. - The company has a strong order backlog of 58 billion yuan, reflecting a year-on-year growth of 28.8%. The TIDES business significantly contributed to the growth of the chemical segment, with a revenue increase of 96% year-on-year [4][5]. - The company expects a revenue forecast for 2026 to be between 51.3 billion and 53 billion yuan, with a year-on-year growth of 18-22% for its continuing operations [4][5]. Financial Performance Summary - In 2025, WuXi AppTec's revenue was 45.456 billion yuan, with a gross margin of 47.6%, an increase of 6.16 percentage points year-on-year. The net profit attributable to shareholders was 19.151 billion yuan, reflecting a 102.6% increase year-on-year [4][5]. - The company projects revenues of 52.28 billion yuan for 2026, with a profit growth rate of -8.6% due to high base effects from 2025 [5][6]. - The report highlights a significant improvement in profitability metrics, with a sales net margin of 42.53%, up 18.15 percentage points year-on-year [4][5]. Business Segment Performance - The chemical business generated 36.47 billion yuan in revenue, a 25.5% increase year-on-year, while the TIDES business alone contributed 11.37 billion yuan, marking a 96% increase [4][5]. - Revenue from U.S. clients grew by 34.3% to 31.25 billion yuan, while revenue from Europe and China saw slight declines [4][5]. - The report emphasizes the company's strong position in the global supply chain, unaffected by recent geopolitical tensions and trade conflicts [4][5]. Future Outlook - WuXi AppTec aims to enhance its technological capabilities and operational efficiency, with capital expenditures projected to reach 6.5-7.5 billion yuan in 2026 [4][5]. - The company anticipates adjusted free cash flow to be between 10.5 billion and 11.5 billion yuan in 2026, indicating strong cash generation potential [4][5]. - The report forecasts continued growth in the CRDMO sector, supported by a robust pipeline and global scale effects, positioning WuXi AppTec to lead the CXO industry [4][5].

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec achieved a record high in performance for the year 2025, with total revenue reaching 454.56 billion yuan, a year-on-year increase of 15.8%. The adjusted non-IFRS net profit was 14.96 billion yuan, up 41.3%, while the net profit attributable to shareholders was 19.15 billion yuan, reflecting a significant increase of 102.65% [4][5]. - The company reported a strong order backlog of 58 billion yuan, a year-on-year growth of 28.8%, driven by the TIDES business, which saw a revenue increase of 96% to 11.37 billion yuan [4][5]. - The revenue contribution from U.S. clients grew by 34.3% to 31.25 billion yuan, while European revenue decreased by 4% [4][5]. - For 2026, WuXi AppTec expects total revenue to be between 513 billion and 530 billion yuan, with a year-on-year growth of 18-22% in continuing operations [4][5]. Financial Performance Summary - In 2025, the company achieved a gross margin of 47.64%, an increase of 6.16 percentage points year-on-year, and a net profit margin of 42.53%, up 18.15 percentage points [4][5]. - The projected financials for 2026 include total revenue of 52.28 billion yuan, with a growth rate of 15%, and a net profit of 17.49 billion yuan, reflecting a decrease of 8.6% [5][6]. - The company’s EBITDA for 2025 was 27.87 billion yuan, with expectations for continued growth in subsequent years [7].

无锡药明康德新药开发股份有限公司 2025 年年度股东会、2026 年第一次 A 股类别股东会及 2026 年第一次 H 股类 别股东会 会议材料 二〇二六年四月 1 无锡药明康德新药开发股份有限公司 股东会会议须知 为了维护全体股东的合法权益、保障股东依法行使股东权利，确保股东会的 正常秩序和议事效率，根据中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司股东会规则》及《无锡药明康德新药开发股份有限公司章程》《无锡 药明康德新药开发股份有限公司股东会议事规则》，特制订本须知。 一、公司设董事会办公室，具体负责会议有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益，确保会议正常秩序， 提高议事效率为原则，认真行使法定权利并履行法定职责。 三、为保证股东会的严肃性和正常秩序，除依法出席会议的公司股东（或其 授权代表）、董事、高级管理人员、见证律师和董事会邀请参会的人员外，公司 有权依法拒绝其他人士入场。 四、为及时、准确统计出席股东会的股东人数及所持有表决权的股份数量， 出席会议的股东（或其授权代表）请按照股东会通知中载明的会议登记办法在会 议召开前向董事会办公室办理签到登记手续。 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2026-015 无锡药明康德新药开发股份有限公司 关于召开2025年年度股东会、2026 年第一次 A 股类别股东 会及 2026 年第一次 H 股类别股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年年度股东会 、2026 年第一次 A 股类别股东会及 2026 年第一次 H 股 类别股东会 股东会召开日期：2026年4月28日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 至2026 年 4 月 28 日 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2026 年 4 月 28 日 14 点 00 分 开始依次召开 2025 年年 度股东会、2026 年第一次 A 股类别股东会及 2026 年第一次 H 股类别股东会 召开地点：上海外高桥喜 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) for both A-shares and H-shares [7]. Core Insights - The company reported a revenue of 45.456 billion RMB for 2025, representing a year-over-year increase of 15.84%. The net profit attributable to shareholders was 19.151 billion RMB, up 102.65% year-over-year, and the adjusted non-IFRS net profit was 14.957 billion RMB, reflecting a 41.33% increase [1][5]. - The company expects a revenue growth guidance of 18-22% for 2026, supported by a strong order backlog and anticipated acceleration in growth for 2026-2027 [2][3]. - The TIDES business segment is projected to maintain high growth, with a revenue of 36.47 billion RMB in 2025, marking a 25.5% year-over-year increase, driven by a significant rise in orders and customer engagement [3][4]. Summary by Sections Financial Performance - For 2025, the company achieved a revenue of 45.456 billion RMB, with a net profit of 19.151 billion RMB, and an adjusted non-IFRS net profit of 14.957 billion RMB [1][5]. - The company anticipates revenues of 51.3-53 billion RMB for 2026, with a continued focus on maintaining a stable adjusted non-IFRS net profit margin [2]. Business Segments - WuXi Chemistry's revenue for 2025 is expected to reach 36.47 billion RMB, with a non-IFRS gross margin of 52.3%, driven by the TIDES segment's growth [3]. - The WuXi Testing and WuXi Biology segments are projected to stabilize, with revenues of 4.04 billion RMB and 2.68 billion RMB respectively for 2025, and expected growth rates of around 10% for 2026 [4]. Valuation and Estimates - The company is valued at 334.81 billion RMB for A-shares and 381.7 billion HKD for H-shares, with a target price of 112.21 RMB and 127.93 HKD respectively [5][12]. - The earnings per share (EPS) estimates for 2026, 2027, and 2028 are projected to be 5.66 RMB, 6.72 RMB, and 7.88 RMB respectively, reflecting an upward adjustment due to better-than-expected growth in the TIDES segment [5][11].